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Fatigue is a frequent symptom in several inflammatory
diseases, particularly in rheumatic diseases. Elements of
disease activity and cognitive and behavior aspects
have been reported as causes of fatigue in patients
with rheumatoid arthritis. Fatigue could be associated
with activity of inflammatory rheumatism. Indeed,
biologic agents targeting inflammatory cytokines are
effective in fatigue. Fatigue is also associated with pain
and depressive symptoms. Different pathways could be
involved in fatigue and interact: the immune system
with increased levels of pro-inflammatory cytokines
(interleukin-1 and −6 and tumor necrosis factor alpha),
dysregulation of the hypothalamic-pituitary-adrenal axis
and neurological phenomena involving the central
and autonomic nervous systems. A pro-inflammatory
process could be involved in pain and behavioral
symptoms. Inflammation could be a common link
between fatigue, pain, and depression.diseases: in rheumatoid arthritis (RA), it is an important
outcome to evaluate according to OMERACT [6], and itIntroduction
Fatigue is usually defined as a state of exhaustion and
decreased strength accompanied by a feeling of weari-
ness, sleepiness, and irritability, with a cognitive compo-
nent [1]. A physiological fatigue state, occurring after
strong physical effort, sends a signal to the body to bring
it to rest to rescue the exhausted tissues (that is, the
muscles). Unlike normal fatigue, pathological fatigue
does not improve with rest. This kind of fatigue is seen
in most acute and chronic inflammatory diseases, in-
cluding arthritis.
This review discusses the place of fatigue in various
inflammatory diseases but also the possible link with
inflammation, pain and depression. We explain this* Correspondence: francis.berenbaum@sat.aphp.fr
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and discuss how inflammation could have a role in the
three other domains - fatigue, stress or depression, and
pain. We searched for articles in MEDLINE via PubMed
with the key words ‘inflammation’, ‘fatigue’, ‘pain’,
‘depression’, ‘rheumatologic diseases’, ‘chronic fatigue
syndrome’ and ‘treatment’. The search was completed by
a hand search of references of the most relevant studies
or published reviews.Multidimensional and multicausal aspects
of fatigue
Fatigue is a multidimensional concept and has various
causes. In rheumatic diseases, the association between
fatigue and pain has been well established [2–4]. High
fatigue is most often associated with high pain, and
fatigue and pain seem to be synchronous [2, 5]. The link
between fatigue and disease activity is less clear. First,
fatigue is clearly a symptom included in rheumatic
has been associated with the Disease Activity Score in
28 joints (DAS28) and the Clinical Disease Activity
Index [7]. In spondyloarthritis (SpA), fatigue is part of
the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) and appears more strongly related to the dis-
ease process than patient-related variables [8]. Further-
more, in anti-neutrophil cytoplasmic antibody-associated
vasculitis, fatigue was associated with increased levels of
C-reactive protein (CRP) [9]. However, a systematic re-
view of fatigue in RA found no link between it and some
characteristics of inflammatory activity, such as erythro-
cyte sedimentation rate or DAS28 [2]. Of note, Lee et al.
[10] described a subgroup of RA patients with well-
controlled disease but high persistent levels of fatigue
(34 %).
These discrepancies could be explained by the variable
definitions of fatigue or its multidimensional aspect. In-
deed, several aspects can affect fatigue: illness-related
characteristics (pain, inflammation, disease activity andThis article is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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related quality of life, sleep quality), cognitive and emo-
tional impairment (anxiety and depression) and personal
components (gender, age, social support, work and en-
vironment) (Fig. 1a) [2, 11–14]. The multidimensional
nature of fatigue was well described by Hewlett et al.
[13] in their conceptual model of the interaction be-
tween fatigue and three components - disease process,
cognitive and behavior aspects, and personal life issues -
with a bidirectional path suggesting interrelationships
among these components. In this model, pain wasA
B
Fig. 1 Model of interactions between fatigue, pain and psychological disturb
and psychological disturbance in inflammatory arthritis. (b) Conceptual mode
disturbance in inflammatory rheumatism. The potential mechanisms of action
could be involved in fatigue, pain and mood disorders. HPA, hypothalamic-piincluded in the disease process and could cause fatigue
but could also interact with other factors such as the in-
flammatory process (responsible for pain, joint damage
and disability), anemia and sleep disturbance [2, 9, 13–15].
Conversely, in RA, fatigue seemed associated more with
the global assessment of RA or pain than inflamma-
tory components such as erythrocyte sedimentation
rate or swollen joint count, perhaps because of the ef-
fect of sleep disturbance or reduced physical activity
on fatigue [3, 4, 16, 17]. Among the other components of
the Hewlett et al. model, cognitive and behavioral factorsance. (a) Conceptual model of clinical interactions between fatigue, pain
l of physiological interactions between fatigue, pain and psychological
in each domain are listed. The increase of inflammatory cytokine levels
tuitary-adrenal; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor
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toms [13]. More recently, Rongen-van Dartel et al. [18]
showed a high level of daily physical activity was associ-
ated with reduced fatigue even after adjustment for pain
and other confounding factors. In SpA, high fatigue was
associated with the disease process, such as high disease
activity (BASDAI), but also personal components, such as
poor quality of life, and other disease activity (bowel
symptoms) [19, 20]. Therefore, fatigue is a subjective
symptom that interacts with the multiple aspects involved
in inflammatory diseases.
Fatigue and inflammation
Fatigue is common among individuals living with a
chronic illness, particularly a disease with an overriding
inflammatory process: rheumatologic diseases such as
RA or SpA, cancers, inflammatory bowel diseases, con-
nective tissue diseases such as systemic sclerosis, systemic
autoimmune diseases, autoimmune type 1 diabetes and
infections [14, 21, 22]. In a descriptive study, fatigue was
more severe in patients with inflammatory bowel disease
than in controls whatever their age [23].
In patients with cancer (acute myelogenous leukemia
and myelodysplastic syndrome), fatigue severity was cor-
related with serum levels of the inflammatory cytokines
interleukin (IL)-6, tumor necrosis factor (TNF)-α and
the IL-1 receptor antagonist (IL-1RA). In lung cancer
patients, IL-8 was a relevant genetic factor of pain and
fatigue [24, 25]. Moreover, the expression of IL-6 and
nuclear factor-kappa B (NFκB) was increased in oncol-
ogy patients with sleep disturbance [26]. In these pa-
tients, inflammation-induced fatigue could be explained
by cancer treatments (radiation, chemotherapy) but also
by secretion of inflammatory cytokines by the tumor
[27]. Even after chemotherapy or radiation treatments,
fatigue could persist for up to 10 years, when levels of a
number of pro-inflammatory plasma markers, including
IL-6, IL-1RA, CRP and soluble TNF receptor type II,
were high [27, 28]. A cumulative effect of levels of cyto-
kines corresponded to the number of days with fatigue
in both breast and prostate cancer patients [28]. As well,
circulating T lymphocytes were increased in number,
with no alteration in immune cells [28]. A recent review
described fatigue occurring with inflammation before,
during and after treatment with several cancers. Fatigue
was well correlated with high levels of inflammatory per-
ipheral cytokines (IL-6, IL-1 and TNF), which could sig-
nal the central nervous system (CNS) and generate
fatigue or other behavioral symptoms [29].
For some authors, the link between inflammation and
fatigue is less clear. A subgroup of patients with high
fatigue and high depression harbored a minor allele for
the anti-inflammatory IL-4 [30]. Moreover, fatigue was
associated with some immunotherapies for HIV/AIDS,such as interferon (IFN)-α and IL-2; about half of 317
patients living with HIV/AIDS reported high levels of
fatigue. In this study, plasma TNF levels were lower
with antiretroviral therapy, CD4+ T-cell counts of at
least 200 cells/mm3 and undetectable viral loads; however,
on multivariable analyses, plasma levels of none of the
cytokines evaluated was significantly associated with
fatigue [10].
However, the replication of studies showing an associ-
ation between expression of genes or inflammation cyto-
kines and fatigue regardless of chronic illness suggests
that inflammation could play a role in the fatigue ex-
perience (Fig. 1b).
Fatigue in chronic rheumatologic diseases
Unusual and chronic fatigue with various etiologies was
described for 27 % of patients in a primary care clinic
[31]. Fatigue is common in RA, SpA, Sjögren syn-
drome, systemic lupus erythematosus and vasculitis,
although most publications concerned fatigue in RA
or SpA [9, 14, 32–35]. In RA and SpA, the frequency of
fatigue ranged from 42 % to 80 % depending on the defin-
ition and methods of assessment [1, 4, 8, 36–39]. For 75 %
of patients with ankylosing arthritis and 50 % of those
with RA, fatigue was considered severe [4, 39].
Several methods of evaluation have been used to
investigate fatigue in rheumatologic diseases [14]. The
simplest and quickest scale is the visual analog scale
(VAS; scores from 0 to 100; the higher the score, the
greater the fatigue), but this is a unidirectional scale.
Multidirectional scales developed to include the different
aspects of fatigue are the Medical Outcomes Study Short
Form 36 (SF-36) vitality subscale (four questions; scores
from 0 to 100; the higher the score, the lower the
fatigue), the Functional Assessment of Chronic Illness
Therapy Fatigue Scale (domains physical, social/family,
emotional and functional; scores from 0 to 52; the higher
the score, the lower the fatigue), the Profile of Mood
States, the RA-specific Multidimensional Assessment
of Fatigue (MAF) scale, the Multidimensional Fatigue
Inventory, the Brief Fatigue Inventory, and the Fatigue
Severity Scale [40–42]. With the VAS scale, the mean
fatigue level in patients with RA was 42.1 [43].
Classical treatments of RA and SpA consist of phar-
macological treatments to control inflammation and
multidisciplinary interventions such as cognitive behav-
ioral therapy and physical exercises to reduce symptoms
and maximize self-management [44]. Among pharmaco-
logical treatments known to reduce disease activity in
RA, disease-modifying antirheumatic drugs (DMARDs),
such as methotrexate and leflunomide, or biologic
treatments, such as anti-TNF (infliximab, adalimumab,
etanercept, golimumab and certolizumab), anti-IL-6
(tocilizumab), CTLA4 immunoglobulin (abatacept) and
Table 1 Possible mechanisms involved in fatigue
Endocrine system Dysregulation of HPA axis and resistance to
glucocorticoids
Thyroid insufficiency
Central nervous system Decrease or polymorphism of
neurotransmitters
Peripheral nervous system Alteration of autonomic system
Stimulation of vagus nerve via microbiota or
inflammation
Anemia Decrease of tissue oxygenation
Inflammation Increase of levels of pro-inflammatory
cytokines (IL-1, IL-6, IL-8 and TNF)
Proliferation of immune cells
Oxidative stress Excess formation of free radicals
Treatments Possible side effects
HPA hypothalamic-pituitary-adrenal, IL interleukin; TNF tumor necrosis factor
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disorders as well as fatigue, although the overall effect
size of biotherapies on fatigue was small (effect size =
0.45; 95 % confidence interval 0.31 to 0.58) [4, 45, 46].
More recently, new biologic therapies have shown effi-
cacy for fatigue: FACIT-Fatigue and SF-36 vitality scales
were improved with secukinumab, an antibody against
IL-17, and tofacitinib, an oral Janus kinase inhibitor
[47, 48]. The placebo effect on fatigue was seen in our
meta-analysis of the effect of biotherapies on fatigue:
scores ranged from 1.04 ± 22.6/100 (DEO19 study) to
11.57 ± 21.92/100 (REFLEX study) [46]. Wells et al. [49]
found that 69, 84 and 90 % of American College of
Rheumatology 20/50/70 responders receiving abatacept,
respectively, had a >20 % improvement in fatigue accord-
ing to the VAS. So even if the level of concordance be-
tween fatigue and disease activity was high, 10 % to a third
of patients had fatigue whereas disease activity improved.
With secikinumab, however, patients reporting increased
pain showed worsened fatigue according to both fatigue
scores [48]. After 3 months of anti-TNF therapy for RA,
fatigue was decreased in patients but was independent of
the level of CRP: on multiple regression, only global health
and tender joint count explained 34 % of the variance in
fatigue [50]. Otherwise, a randomized controlled trial
showed significant benefits of an exercise program on fa-
tigue scores, quality of life, pain and sleep quality [51].
After six weekly sessions of behavioral therapy and a con-
solidation session, RA patients with initial VAS fatigue
score ≥6/10 reported better fatigue scores than controls
(MAF and VAS scales) and better perceived fatigue sever-
ity, coping, disability, depression, helplessness, self-efficacy
and sleep [52].
Link between fatigue and pain
Fatigue and pain are two common symptoms in RA, and
the link between fatigue and pain in it has been described
[2–4, 53]. In a cross-sectional study, VAS fatigue score was
mainly correlated with VAS pain score; pain was most
strongly associated with the five variables explaining fatigue
[4]. Garip et al. [53] confirmed this association, showing
that fatigue intensity in RA patients was strongly correlated
with VAS pain score and DAS28, with greater correlation
between fatigue and pain scores than between fatigue score
and DAS28. Moreover, after treatments (DMARDs or bio-
logic agents), the decrease in VAS fatigue score was corre-
lated with ameliorated pain and improved DAS28 score
[4]. For Wolfe et al. [11], pain was a strong independent
predictor of fatigue with sleep disturbance, depression,
tender joint count and disability by the health assessment
questionnaire. Among the variables usually linked to
fatigue, pain was a better predictor of fatigue [54].
To examine the bidirectional effect of pain and fatigue,
van Dartel et al. [5] conducted a prospective study ofpatients with established RA who received DMARDs
and/or biologic agents; pain and fatigue were measured
monthly for 1 year. Pain and fatigue levels fluctuated,
and the change in fatigue level was positively associated
with change in pain level during the same month. How-
ever, change in fatigue level was not related to a change
in pain level that occurred 1 month earlier, and change in
pain level was not related to a change in fatigue level
1 month earlier [5]. Moreover, in a cohort of patients with
fibromyalgia, usually considered a non-inflammatory
disease, pain and fatigue scores were correlated (r = 0.45,
P < 0.001) and, in the prospective analysis at 1 week,
daily pain evaluation predicted increased fatigue level
reported the next day (more than depression or daily
sleep quality) [16].
Fatigue and pain pathways: role of inflammation
Role of inflammation in fatigue
The mechanisms of fatigue are complex and have been
studied in animal models and humans. Because fatigue
could be explained by loss of muscle mass or altered
mood, Norden et al. [55] proposed a model to discrimin-
ate between these phenomena: some colon tumor-bearing
mice demonstrated signs of fatigue (decreased voluntary
wheel-running activity) and depressed mood (resignation
and anhedonia), with no association with decreased nor-
malized contractile properties of skeletal muscle of the
limb. So fatigue seemed linked more to behavior than
muscle activity.
Inflammation could play an important role (Table 1).
The injection of IL-1 in murine models decreased social
exploration and increased hypersomnia and body weight
loss, which were all improved by the administration of
anti-inflammatory IL-1RA or IL-10 [56, 57]. Moreover,
in the model of tumor-induced fatigue in mice seen
earlier, fatigue was associated with increased levels of
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cline, an anti-inflammatory agent, improved grip strength
without reducing tumor growth or muscle mass [55].
The role of inflammation in fatigue has also been
shown in patients. Indeed, in those with chronic fatigue
syndrome (CFS), fatigue intensity was associated with
high circulating IL-8 levels [58]. Moreover, in an obser-
vational study of military personnel with insomnia, CRP
level was reduced more in the restorative sleep group
than in those with persistent insomnia [59]. In RA pa-
tients, a meta-analysis of therapeutic studies showed that
inhibiting levels of some pro-inflammatory cytokines by
biologic agents such as anti-TNF, anti-IL-6, CTLA4 im-
munoglobulin or anti-CD20 significantly decreased the
level of fatigue whatever the therapy [46].
Otherwise, fatigue could be due to inflammation-
induced anemia by decreasing iron levels mediated byFig. 2 Mechanisms of interaction between peripheral inflammation, the nerv
the fatigue process. In the HPA axis, the hypothalamus contains neurons that
adrenocorticotropic hormone (ACTH) by the pituitary gland. ACTH stimulates
and catecholamines by the adrenal medulla of the adrenal gland. Cortisol cou
inhibit many functions of leukocytes and the production of pro-inflammatory
have pro-inflammatory properties and IL-1, IL-6 and tumor necrosis factor (TN
inflammation: the sympathetic neurons of the autonomic nervous system
pro-inflammatory cytokines could enter central nervous system (CNS) areas b
messengers to induce cytokine activity in the brain. With excess inflammationIL-6-induced hepcidin and thyroid insufficiency or de-
creased hypothalamic-pituitary-adrenal (HPA) axis activ-
ity and resistance to glucocorticoids (Fig. 2 and Table 1)
[27, 60, 61]. In this system, the release of adrenocortico-
tropic hormone is affected by the sleep cycle, but in
some diseases, the circadian cortisol cycle is abnormally
flattened [61]. Therefore, neurological phenomena could
be involved in fatigue (Table 1). The role of CNS neuro-
transmitters was mentioned in recent reviews [27, 62,
63]: fatigue was found to be related to polymorphism in
catechol-O-methyltransferase (COMT) and low levels of
tryptophan, an amino acid involved in the synthesis of
serotonin or impaired brain dopamine and norepineph-
rine transmission [27, 62, 63]. In parallel, the autonomic
activity was altered in a model of fatigue induced by a
cognitive task, the Kana Pick-out Test (alternating open
and closed eyes): VAS fatigue score was associated withous system and the hypothalamic-pituitary-adrenal (HPA) axis involved in
synthesize corticotropin-releasing hormone (CRH), which regulates
the synthesis of glucocorticoids such as cortisol by the adrenal cortex
ld have a negative feedback mechanism on the brain. Glucocorticoids
cytokines (interleukin (IL)-6 and IL-1) by immune cells. ACTH and CRH
F)-α activate the HPA axis. The peripheral nervous system can affect
(ANS) secrete pro- and anti-inflammatory neuropeptides. These
y the permeable blood–brain barrier or facilitate the release of second
, the activity of some CNS neurotransmitters could be altered
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sinus modulation as evaluated by electrocardiography
[64]. Moreover, this model of induced fatigue activated
the dorsolateral prefrontal cortex and cingulate cortex as
assessed by functional magnetic resonance imaging
(MRI) [64, 65].
Systemic inflammation could affect these central mecha-
nisms. Under some circumstances, such as chronic anxiety,
posttraumatic stress, and local or general inflammation dis-
eases, the HPA axis was deregulated and the persistent se-
cretion of corticoids induced glucocorticoid resistance [66].
The HPA axis has also been shown to interact with the im-
mune system (Fig. 2) [61]. Moreover, although the brain is
considered an immunologically privileged site, systemic
infection or inflammation can have a profound effect on
the CNS. In an animal model of inflammation, the pe-
ripheral administration of lipopolysaccharide increased
IFN-stimulated genes in the brain [66, 67]. Peripheral pro-
inflammatory cytokines could have a direct action when
they enter CNS areas where the blood–brain barrier is per-
meable and an indirect action when they facilitate the re-
lease of second messengers to induce cytokine activity in
the brain or when they activate the vagus or other afferent
nerves [14]. TNF-α could participate in microglial activa-
tion in promoting rolling and adhesion of leukocytes along
cerebral endothelial cells, which negatively affects dopa-
minergic neurotransmission [27, 63, 66–68]. However,
anti-TNF agents are unable to penetrate the blood–brain
barrier [69]. Inflammatory cytokines would also be respon-
sible for a relative deficit in tetrahydrobiopterin used in the
synthesis of the neurotransmitters dopamine, norepineph-
rine and serotonin [63]. The CNS releases norepinephrine,
which is responsible for upregulating IL-1, IL-6 and TNF
[66]. However, most studies examined acute inflammation,
and the role of neurotransmitters in chronic inflammation
is not well established. A bidirectional interaction between
the neuroendocrine system and peripheral inflammation
could play a role in fatigue.
Role of inflammation in pain
Pain has been investigated in animal models and hu-
mans. In animal models, pain could result from complex
interactions between joint inflammation and altered pain
processing: a peripheral mechanism (for example, in-
creased innervation of the synovium; increased dorsal
root ganglia expression of substrance P, calcitonin gene-
related peptide and neuropeptide Y; increased expression
of tyrosine kinase receptor A for nerve growth factor
and neuronal death) and central mechanism (for ex-
ample, nociceptive pathway activity, increased sensitivity
of spinal neurons via glian, and activation via interleukin
(IL-1, IL-6 and TNF), opiod expression in ganglia, cen-
tral sensitization). Dopamine and serotonin systems are
also involved in pain: COMT gene expression andpolymorphisms of serotonin transporter genes were
found associated with pain [62]. Patients with RA
showed production of peripheral pain agents, pro-
inflammatory cytokines (IL-1, IL-6 and TNF with differ-
ent actions on responsiveness of Aδ-fibers, C-fibers and
the effect of neutralization on mechanical hyperalgesia)
and nerve growth factor in synovium or synovial fluid,
which sensitized peripheral receptors [70]. TNF-α
injected in mouse joints induced persistent sensitization
of nociception with noxious stimuli, with a dose-
dependent effect, with prevention by injection of an anti-
TNF agent [71]. Endogenous opioids, somatostatin, lipid
mediators and anti-inflammatory cytokines (IL-4 and IL-
10) were also present in synovial tissue, but their roles re-
main to be determined. Central pain processing was in-
creased in RA patients, with a change in neuronal
adaptive response and increased activity of the thalamus,
secondary sensory cortex and limbic system, which could
be modulated by emotional processing or low mood [70,
72]. Proinflammatory cytokines could have a direct action
on pain via sensory neurons or an indirect action via in-
flammatory mediators such as prostaglandins [70].
Role of inflammation in altered central nervous
system activity
Because fatigue is also often associated with anxiety and de-
pression in inflammatory rheumatism, it may be due in part
to a neurological phenomenon. Pro-inflammatory cytokines
could be involved: administration of IL-1β, IL-6 or TNF-α
in mice increase behavioral symptoms such as social ex-
ploration [56, 68]. A review showed that blood levels of
some inflammatory cytokines, such as mitogen-stimulated
cytokines and adipokines, were higher with depression
[68]. A meta-analysis of 24 publications reporting on
levels of cytokines in depressed patients found increased
levels of TNF-α and IL-6 but not IL-1β, IL-4, IL-2, IL-8,
IL-10 or IFN-γ [73]. In some of these studies, however,
this association could represent a subset of patients; for
example, those with a high degree of depression, who were
older and had comorbidities [74]. In older patients of the
Rotterdam study, despite no association between blood
levels of IL-6 and CRP and depressive symptoms, high
levels of these inflammatory proteins predicted depressive
symptoms 5 years later [74]. Moreover, in pooling the data
for five placebo-controlled trials, Iyengar et al. [75] showed
that treatment with nonsteroidal anti-inflammatory drugs
(the ibuprofen or naproxen group and the celecoxib group)
was associated with decreased depression score and
showed a trend to changed classification of depression at
6 weeks. Moreover, antidepressive agents might inhibit the
production of pro-inflammatory IL-6 and stimulate anti-
inflammatory IL-4, IL-10 and IL-1RA [76]. However, levels
of the proinflammatory cytokines could also be altered by
stressors or lifestyle factors associated with depression.
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sonal loss or social rejection was associated with levels of
pro-inflammatory IL-6 and TNF-α and also CRP, especially
in depressed patients [73].
Stress was also associated with high levels of the pro-
inflammatory intracellular transcription factors NFκB
and inhibitor of kB and modulated genome-wide expres-
sion levels [66]. Thus, inflammation and depression
seem to be linked, but which one affects the other is dif-
ficult to distinguish and probably there is an interaction
between both.
Inflammation: a potential link between fatigue,
depression and pain
Although fatigue, stress or depression, and pain have
complex and various mechanisms of action, some in-
flammatory cytokines are found associated with these
three domains, so inflammation may be their potential
link. The association between these symptoms has been
documented in various medical conditions: classical in-
flammatory diseases such as rheumatic diseases, cancer
or infections but also CFS, metabolic disorders or de-
pression, which exhibit low-grade inflammation [77].
Some authors found that in RA, fatigue, mood disor-
ders and pain are clinically associated [2]; IL-1 level was
higher in cerebrospinal fluid of patients than controls
and the increased level was correlated with fatigue [78].
Biologic treatments are efficacious and can decrease
levels of markers of inflammation such as CRP; toci-
lizumab is especially efficacious because of its action on
IL-6 involved in the synthesis of CRP [79]. Thus, de-
creased systemic inflammation could be one of the mech-
anisms of action improving fatigue, pain and mood
disorders.
Moreover, in a cohort of 1,466 European patients with
advanced cancer, increased CRP level was associated
with pain and fatigue (rho = 0.154 and 0.197, respect-
ively) [80]. In ovarian cancer patients, diurnal and noc-
turnal cortisol and plasma IL-6 levels decreased (became
normal) during the first year following surgery, and this
decrease was associated with decreased fatigue and
depression [81].
Another model of the association of fatigue, pain and
depression is CFS. Recently, a review showed that
chronic inflammation could explain, in part, the sickness
behavior [57]. In this pathology, with increased sen-
sitivity to pain and with sickness behavior, inflammatory
cytokines could have an effect on nociception. Such
cytokines appeared to be critical mediators of hyperalgesia
in a lipopolysaccharide-induced animal model [82, 83]. In
CFS, the levels of neopterin, a marker of cellular immune
system activation, IL-1 and TNF were correlated with
fatigue and depression [84]. Brain inflammation could have
a role in CFS, in part by activating microglia or astrocytes.Indeed, the density of 11C-(R)-(2-chlorophenyl)-N-methyl-
N-(1-methylpropyl)-3-isoquinoline-carboxamide, a marker
of neuroinflammation, was increased in some areas of the
brain, in particular the cingulate cortex, in patients with
CFS compared with healthy patients. Its increased level in
the thalamus was correlated but not significantly with pain
score and fatigue sensation (P = 0.0683) [85].
We have emerging evidence of the role of microbiota
in the pathogenesis of autoimmune disease, particularly
in rheumatologic disease [86]. Recently, Galland [87]
proposed a schema in which the gut microbiome could
affect CFS or fibromyalgia: the bacterial components
could excessively stimulate the innate immune system
and induce systemic and CNS inflammation by produ-
cing neurotoxic metabolites or could directly stimulate
afferent neurons of the nervous system to send signals
to the brain via the vagus nerve. Then, the gut micro-
biome could affect the HPA axis and be responsible for
fatigue and pain in these diseases.
Moreover, it is interesting to highlight brain areas
involved in these various domains. With the Kana Pick-
out Test, in the model of induced-fatigue previously
described, the dorsolateral prefrontal cortex and cingu-
late cortex were activated as seen on functional MRI
[64, 65]. In adults, noxious stimulation increased MRI
activity in primary somatosensory cortices, the anterior
cingulate cortex, bilateral thalamus, and divisions of the
insular cortices [88]. There is a common area for neural
activity in experiences of physical pain, induced fatigue,
depressive mood and bacterial endotoxin-induced in-
flammation (with increased IL-6 level): the anterior in-
sula, believed to play a role in consciousness and in
emotion or regulation of the body’s homeostasis, and
anterior cingulate cortex, known to be involved in auto-
nomic and cognitive functions [64–66]. A common
CNS pathway would be a link between fatigue and pain,
and among the different mechanisms of fatigue, the ac-
tion of inflammation on the CNS could be one of these
pathways.
Conclusion
Fatigue and pain are two symptoms frequently present
in acute or chronic high-grade inflammatory diseases
such as infection, rheumatoid diseases or cancers but
also low-grade inflammatory diseases such as CFS.
These symptoms are often associated with depression. In
all these diseases, several markers of inflammation have
been highlighted, and among various and complex
mechanisms of action, inflammation could be one of the
common links between fatigue and pain among various
and complex mechanisms. In rheumatic diseases, de-
creasing inflammation may improve fatigue and pain.
Peripheral inflammation localized at organs is associated
with central neurological phenomena. The inflammatory
Louati and Berenbaum Arthritis Research & Therapy  (2015) 17:254 Page 8 of 10cytokines and cells interact with the CNS: peripheral in-
flammation can provoke fatigue and pain, and an altered
neuroendocrine system could modulate inflammation.
Because of multiple aspects of fatigue among patients
and multiple mechanisms of action that could be in-
volved, a future perspective would be to identify some
phenotypes of fatigue to better target this treatment.Note: This article is part of the series ‘At the interface between
immunology and neurology in rheumatic diseases’, edited by
Rainer Straub. Other articles in this series can be found at
http://arthritis-research.com/series/neurology.Abbreviations
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